The chemical class labeled AU042671 Activators encompasses compounds that are designed to interact with and enhance the function of the molecular target identified by the code AU042671. Initial identification of these activators typically relies on a robust high-throughput screening (HTS) process, wherein a large library of diverse compounds is assayed for their ability to augment the activity of AU042671. This screening often uses enzymatic or binding assays that produce a detectable signal, such as a colorimetric or luminescent change, to indicate activation. Compounds that demonstrate a clear ability to increase the activity of AU042671 are selected for further evaluation. The ensuing secondary assays are more focused and rigorous, aiming to confirm the initial observations and to assess the specificity and potency of the activation effect. These secondary assays not only validate the results from the HTS but also help to exclude any non-specific interactions that may have been picked up as false positives in the initial screening.
Upon establishing a group of promising AU042671 activators, detailed studies are undertaken to elucidate the interaction between these molecules and the AU042671 target. Structural determination techniques, such as X-ray crystallography or NMR spectroscopy, are instrumental in mapping the precise location and nature of the binding site, and in observing the molecular configuration of both the activator and the target in their bound state. This structural information is crucial for understanding how these activators work at a molecular level and can inform the design of more efficacious compounds. In parallel, kinetic analyses using SPR or ITC provide quantitative data on the dynamics of the interaction, including binding affinities and rates. These kinetic parameters are important for understanding the strength and duration of the activation effect. Furthermore, structure-activity relationship (SAR) studies systematically modify the chemical structure of the activators to identify which parts of the molecule are essential for activity and which can be altered to enhance the interaction with AU042671. Through this methodical approach, the chemical moieties that are critical for the activation of AU042671 are determined, which in turn helps to refine the profile of the AU042671 activators and delineate them as a unique chemical class.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, preventing cAMP degradation. This leads to sustained activation of pathways involving cAMP, potentially enhancing AU042671 activity through cAMP-dependent protein kinase (PKA) signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which could lead to the phosphorylation and activation of AU042671, assuming it is a PKC substrate or involved in a pathway downstream of PKC. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, potentially enhancing AU042671 activity if it is regulated by calcium-dependent signaling pathways. | ||||||
Spermine | 71-44-3 | sc-212953A sc-212953 sc-212953B sc-212953C | 1 g 5 g 25 g 100 g | $61.00 $196.00 $277.00 $901.00 | 1 | |
Spermine can modulate ion channels and may enhance AU042671 activity if the protein is regulated by cellular ion dynamics or is part of a signaling pathway affected by polyamines. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and if AU042671 is involved in signaling pathways that are sensitive to microtubule dynamics, its activity could be enhanced as a result of paclitaxel's stabilizing effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could lead to increased activity of AU042671 if it is involved in a pathway negatively regulated by PI3K or downstream of Akt signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and could enhance AU042671 if the protein is regulated by pathways that are responsive to ERK signaling, as U0126 would shift the balance of signaling towards AU042671 activation. | ||||||